ClinicalTrials.gg
Active, not recruitingNCT07063316Updated Sep 16, 2026

SGLT2 Inhibitors and Renal Anemia in Japan: RWD

An observational study in Chronic Kidney Disease, sponsored by Boehringer Ingelheim. Active, not recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Boehringer Ingelheim · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
15,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim — none open to participants now, 4 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Boehringer Ingelheim.

Started
2025
with 2 others
Observational
3 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, this one is one of 3 that started in 2025, is one of 3 observational ones, and was the 12th registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim as a file.
02

Study summary

The objectives of the study are:

  1. To evaluate the association between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor use and the occurrence of anemia in patients with chronic kidney disease (CKD) using a nested case-control design with incidence density sampling.
  2. To evaluate anemia-related outcomes using a nested case-control-based analytical framework, including assessment of within-subject changes in anemia-related treatments and healthcare costs by comparing the period after study entry with the period after the index date (for cases) or matched reference date (for controls), and comparison according to SGLT2 inhibitor use:

A) Prescription patterns and treatment regimens for anemia, including analysis of medication types, dosing strategies, and duration of treatments B) Anemia-related healthcare costs C) Change in laboratory values

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chronic kidney disease patients registered in the Medical Data Vision (MDV) database in Japan.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have two consecutive estimated (eGFR) measurements \< 60 mL/min/1.73 m2 at least 92 days apart between April 17, 2014 and October 31, 2022.
  2. Aged 18 years or older at the study cohort entry date.
  3. Have at least one (Hb) measurement at the study cohort entry date or within 183 days before the study cohort entry date.

Exclusion criteria

Exclusion Criteria:

  1. Have less than 183 days of record history before the study cohort entry date.
  2. Have any prescription record for an SGLT2 inhibitor at the study cohort entry date or within 183 days before the study cohort entry date
  3. Have evidence of anemia at the study cohort entry date or within 183 days before the study cohort entry date.

    • (Hb) \< 13.0 g/dL for men or \< 12.0 g/dL for women
    • Hematocrit (Ht) \< 39% for men or \< 36% for women
    • Have a history of prescribed anemia-related medications and treatments at the study cohort entry date or within 183 days before the study cohort entry date.
  4. Have evidence of anemia-causing conditions other than chronic kidney disease (CKD) at the study cohort entry date or within 183 days before the study cohort entry date.
  5. Confirm at least one instance of hemodialysis, peritoneal dialysis, or kidney transplantation at the study cohort entry date or within 183 days before the study cohort entry date.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
15,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • SGLT2 inhibitor users

    Drug: SGLT2 inhibitor

  • SGLT2 inhibitor non-users

Interventions

06

What researchers measure

Primary outcomes

  1. First occurrence of anemia (composite anemia outcomes)

    The composite of anemia outcomes is defined as any of the following: * Hb \< 13.0 g/dL for men or \< 12.0 g/dL for women * Clinical diagnosis of anemia using ICD-10 diagnosis codes * Initiation of anemia treatment (Erythropoiesis-Stimulating Agents (ESAs), Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PH) inhibitors, iron preparations, or red blood cell (RBC) transfusion

    Time frame: From the study cohort entry date to first event occurrence (for cases) or matched reference date (for controls), up to 13 years

Secondary outcomes

  1. Number of administered doses of ESA, HIF-PH inhibitors, iron preparations, and RBC transfusions

    Erythropoiesis-Stimulating Agents (ESAs) Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PH) Red blood cell (RBC) transfusions -outcome evaluated as within-subject changes between pre- and post-index/reference periods

    Time frame: 1, 3, and 6 months after cohort entry and after the index date (cases) or matched reference date (controls)

  2. Anemia-related healthcare costs

    Anemia-related medical costs are defined as the sum of direct medical costs associated with the treatment of anemia. These costs will include medication costs and costs related to RBC transfusion. -outcome evaluated as within-subject changes between pre- and post-index/reference periods

    Time frame: 1, 3, and 6 months after cohort entry and after the index date (cases) or matched reference date (controls)

  3. Frequency of administration of ESA, HIF-PH inhibitors, iron preparations, and RBC transfusions

    -outcome evaluated as within-subject changes between pre- and post-index/reference periods

    Time frame: 1, 3, and 6 months after cohort entry and after the index date (cases) or matched reference date (controls)

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 14, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Dec 25, 2026
CompletionEst.
Dec 25, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07063316
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jul 23, 2025
Primary completion
Dec 25, 2026 (estimated)
Completion
Dec 25, 2026 (estimated)
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion